Company Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.
The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders.
It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize.
Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jul 18, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Alexander Sapir |
Contact Details
Address: 26 Landsdowne Street Cambridge, Massachusetts 02139 United States | |
| Phone | 617 651 8851 |
| Website | fulcrumtx.com |
Stock Details
| Ticker Symbol | FULC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 1680581 |
| CUSIP Number | 359616109 |
| ISIN Number | US3596161097 |
| Employer ID | 47-4839948 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Alexander C. Sapir | Chief Executive Officer, President and Director |
| Alan A. Musso C.M.A., CPA | Chief Financial Officer |
| Curtis G. Oltmans J.D. | Chief Legal Officer, Head of External Affairs and Corporate Secretary |
| Dr. Bradley E. Bernstein M.D., Ph.D. | Founder |
| Dr. Michael R. Green | Founder |
| Dr. Rudolf Jaenisch M.D., Ph.D. | Founder |
| Dr. Tsun-Huei Lee M.D., Ph.D. | Founder |
| Dr. Danny Reinberg | Founder |
| Gregory Tourangeau | Controller and Principal Accounting Officer |
| Dr. Jeffrey W. Jacobs Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 24, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 24, 2026 | 10-K | Annual Report |
| Feb 24, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Jan 12, 2026 | 8-K | Current Report |
| Dec 15, 2025 | 144 | Filing |
| Dec 11, 2025 | 8-K | Current Report |
| Dec 11, 2025 | 424B5 | Filing |
| Dec 10, 2025 | SCHEDULE 13G/A | Filing |
| Dec 10, 2025 | FWP | Free Writing Prospectus |